Manager TitleAgeSince
Chief Executive Officer - 01/04/2026
Chief Tech/Sci/R&D Officer - 17/07/2009
Director of Finance/CFO 60 01/07/2022
Director TitleAgeSince
Director/Board Member 58 09/07/2020
Chairman 68 09/12/2021
Director/Board Member 78 01/09/2004
Change 5-day change 1-year change 3-year change Capi.($)
-1.17%-1.85%-30.52%-3.23% 90.08B
+0.35%-0.58%-21.66%-25.10% 32.91B
-0.45%-4.72%-5.44%-26.99% 13.79B
-0.83%+0.56% - - 9.91B
-4.41%-17.27%-28.52%+493.36% 1.97B
+1.61%-3.34%-31.65%-65.98% 1.41B
0.00%+0.67%+23.15%+3.88% 897M
-0.59%-1.38%-37.63%-27.49% 846M
+0.48%-1.82%+43.31%-32.02% 764M
Average -0.56%-2.37%-11.12%+39.55% 16.95B
Weighted average by Cap. -0.75%-1.00%-25.34%-4.59%
Logo TearLab Corp
TearLab Corporation is an in-vitro diagnostic company. The Company has commercialized a tear testing platform, the TearLab Osmolarity System, which enables eye care practitioners to test for sensitive and specific biomarkers using nanoliters of tear film at the point-of-care. The Company, through its subsidiary TearLab Research, Inc., develops technologies to enable eye care practitioners to test a range of biomarkers (chemistries, metabolites, genes and proteins) at the point-of-care. Its product, the TearLab Osmolarity System, enables the measurement of tear osmolarity in the doctor's office. The TearLab Osmolarity System consists of approximately three components: the TearLab disposable, the TearLab Pen, and the TearLab Reader. The TearLab disposable is a single-use microfluidic microchip. The TearLab Pen is a hand-held device that interfaces with the TearLab disposable. The TearLab Reader is a small desktop unit that allows for the docking of the TearLab Pen.
Employees
-